EPGNF: AI 评分 55/100 — AI 分析 (4月 2026)

Epigenomics AG focuses on developing and commercializing molecular diagnostic products for early cancer detection using liquid biopsy. Their primary product, Epi proColon, is a blood-based test for colorectal cancer screening available in the United States, Europe, and China.

Key Facts: AI Score: 55/100 Sector: Healthcare

公司概况

概要：

Epigenomics AG is a molecular diagnostics company specializing in liquid biopsy for early cancer detection, primarily through its Epi proColon blood test for colorectal cancer. With a focus on epigenetic biomarkers, the company aims to provide minimally invasive screening solutions in the US, Europe, and China, operating in a competitive diagnostics market.

EPGNF是做什么的？

Founded in 1998 in Berlin, Germany, Epigenomics AG is a molecular diagnostics company dedicated to the development and commercialization of innovative liquid biopsy tests for early cancer detection. The company's core technology revolves around analyzing epigenetic biomarkers in blood samples to identify cancer signals at an early stage. Their flagship product, Epi proColon, is a blood-based screening test designed for the early detection of colorectal cancer. Epi proColon is currently available in the United States, Europe, and China, targeting individuals who are unwilling or unable to undergo traditional colonoscopy screening. Beyond Epi proColon, Epigenomics AG is also involved in the development of a blood test for hepatocellular carcinoma. The company also offers Epi BiSKit, a pre-analytical tool that provides reagents for bisulfite-converted DNA preparation, essential for epigenetic analysis. Epigenomics AG's research and development efforts are centered on identifying and validating novel biomarkers in human tissue, with the goal of developing and patenting corresponding in vitro diagnostic blood tests. The company aims to provide convenient and accessible cancer screening solutions, contributing to improved patient outcomes through early detection.

EPGNF的投资论点是什么？

Epigenomics AG presents a focused investment opportunity within the liquid biopsy and early cancer detection market. The company's Epi proColon test addresses a significant unmet need for convenient colorectal cancer screening, particularly among individuals who avoid traditional colonoscopies. However, the company's limited market capitalization of $0.00B and negative P/E ratio of -0.24, coupled with a high negative profit margin of -2479.2%, indicate substantial financial challenges. Growth catalysts include potential expansion into new geographic markets and the development of additional cancer screening tests. The company's success hinges on increasing market adoption of Epi proColon and achieving profitability.

EPGNF在哪个行业运营？

Epigenomics AG operates in the rapidly evolving molecular diagnostics market, specifically within the liquid biopsy segment. This market is driven by the increasing demand for non-invasive cancer screening methods and personalized medicine. The competitive landscape includes established diagnostic companies and emerging players focused on liquid biopsy technologies. Epigenomics AG's success depends on its ability to differentiate its Epi proColon test and gain market share in the colorectal cancer screening market, which is projected to grow significantly due to increasing cancer incidence and awareness.

Medical - Diagnostics & Research

Healthcare

EPGNF有哪些增长机遇？

Expansion into New Geographic Markets: Epigenomics AG has the opportunity to expand the availability of Epi proColon into additional geographic markets beyond the United States, Europe, and China. Focusing on regions with high colorectal cancer incidence and limited access to traditional screening methods could drive significant revenue growth. The global market for colorectal cancer diagnostics is projected to reach billions of dollars, providing a substantial addressable market for Epigenomics AG.
Development of Additional Cancer Screening Tests: Epigenomics AG can leverage its expertise in epigenetic biomarkers to develop and commercialize additional liquid biopsy tests for other types of cancer, such as lung cancer, breast cancer, and prostate cancer. Expanding the product portfolio would diversify revenue streams and reduce reliance on Epi proColon. The market for multi-cancer early detection tests is emerging and represents a significant growth opportunity.
Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with healthcare providers, such as hospitals, clinics, and physician groups, can facilitate the adoption of Epi proColon and other diagnostic tests. Collaborating with healthcare providers can improve market access, increase test utilization, and enhance brand awareness. These partnerships can also provide valuable insights into clinical needs and market trends.
Increased Marketing and Awareness Campaigns: Investing in targeted marketing and awareness campaigns can educate both healthcare professionals and the general public about the benefits of Epi proColon and liquid biopsy for early cancer detection. Raising awareness can drive demand for the test and increase screening rates. Effective marketing strategies include online advertising, social media engagement, and participation in medical conferences.
Advancements in Liquid Biopsy Technology: Continued advancements in liquid biopsy technology, such as improved sensitivity and specificity of biomarker detection, can enhance the performance and clinical utility of Epigenomics AG's diagnostic tests. Investing in research and development to refine the company's technology platform can maintain a competitive edge and attract new customers. These advancements can also lead to the development of more accurate and cost-effective screening solutions.

Market Cap of $0.00B reflects the company's small size and potential volatility.
P/E Ratio of -0.24 indicates that the company is currently unprofitable.
Profit Margin of -2479.2% highlights significant operational losses.
Gross Margin of 75.3% suggests strong pricing power on existing sales, but is offset by high operating expenses.
Beta of 0.84 indicates lower volatility compared to the overall market.

EPGNF提供哪些产品和服务？

Develop and commercialize molecular diagnostic products for early cancer detection.
Focus on liquid biopsy technology using blood samples.
Offer Epi proColon, a blood-based test for colorectal cancer screening.
Provide Epi BiSKit, a pre-analytical tool for bisulfite-converted DNA preparation.
Conduct research and development to identify and validate novel biomarkers.
Patent in vitro diagnostic blood tests.

EPGNF如何赚钱？

Develop and patent diagnostic blood tests for early cancer detection.
Commercialize these tests through direct sales and partnerships with healthcare providers.
Generate revenue from the sale of Epi proColon and other diagnostic products.
Offer pre-analytical tools like Epi BiSKit to support epigenetic analysis.

Individuals at risk for colorectal cancer who are unwilling or unable to undergo traditional colonoscopy.
Healthcare providers, including hospitals, clinics, and physician groups.
Laboratories that perform diagnostic testing.
Research institutions conducting studies on cancer biomarkers.

Proprietary epigenetic biomarker technology.
Patent protection for diagnostic tests and methods.
Established market presence with Epi proColon.
Expertise in liquid biopsy and molecular diagnostics.

什么因素可能推动EPGNF股价上涨？

Ongoing: Increasing adoption of Epi proColon in the US, Europe, and China.
Upcoming: Potential expansion into new geographic markets.
Upcoming: Development and commercialization of new cancer screening tests.
Ongoing: Strategic partnerships with healthcare providers to increase market access.

EPGNF的主要风险是什么？

Ongoing: Intense competition in the molecular diagnostics market.
Potential: Regulatory hurdles and reimbursement challenges for diagnostic tests.
Potential: Patent expiration and biosimilar competition for Epi proColon.
Ongoing: Limited financial resources and negative profitability.
Potential: Changes in healthcare policies and guidelines affecting cancer screening.

EPGNF的核心优势是什么？

Proprietary epigenetic biomarker technology
Epi proColon test addresses an unmet need for non-invasive colorectal cancer screening
Established partnerships in key markets (US, Europe, China)
Expertise in liquid biopsy and molecular diagnostics

EPGNF的劣势是什么？

Limited market capitalization and financial resources
Negative profitability and high operating losses
Reliance on a single product (Epi proColon)
Competition from established diagnostic companies

EPGNF有哪些机遇？

Expansion into new geographic markets
Development of additional cancer screening tests
Strategic partnerships with healthcare providers
Increased marketing and awareness campaigns

EPGNF面临哪些威胁？

Competition from alternative screening methods (colonoscopy, stool-based tests)
Regulatory hurdles and reimbursement challenges
Patent expiration and biosimilar competition
Changes in healthcare policies and guidelines

EPGNF的竞争对手是谁？

BioMark Diagnostics Inc. — Focuses on early cancer detection using metabolomics. — (BMMJ)
Chemung Financial Corp — Financial institution, not a direct competitor in diagnostics. — (CHME)
China Yuchai International Ltd — Engine manufacturer, not a direct competitor in diagnostics. — (CHYPF)
New Gold Inc. — Gold mining company, not a direct competitor in diagnostics. — (NGMC)
Nanostring Technologies Inc — Offers spatial biology solutions for research and diagnostics. — (NSTM)

Key Metrics

MoonshotScore: 55/100

Company Profile

CEO: Noel Thomas Doheny
Headquarters: Heidelberg, DE
Employees: 6
Founded: 2010

AI Insight

AI analysis pending for EPGNF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Epigenomics AG do?

Epigenomics AG is a molecular diagnostics company focused on developing and commercializing blood-based tests for early cancer detection. Their primary product, Epi proColon, is a blood test designed to screen for colorectal cancer in individuals who are unwilling or unable to undergo traditional colonoscopy. The company utilizes epigenetic biomarkers to identify cancer signals in blood samples, providing a minimally invasive alternative for cancer screening. Epigenomics AG aims to improve patient outcomes through early detection and convenient access to cancer screening solutions.

What do analysts say about EPGNF stock?

There is no analyst consensus available for EPGNF in the provided data. The company's financial metrics, including a negative P/E ratio and a high negative profit margin, suggest significant financial challenges. Investors should carefully consider the company's financial performance, growth prospects, and competitive landscape before making any investment decisions. Further research and due diligence are recommended to assess the potential risks and rewards associated with investing in EPGNF.

What are the main risks for EPGNF?

The main risks for Epigenomics AG include intense competition in the molecular diagnostics market, regulatory hurdles and reimbursement challenges for diagnostic tests, potential patent expiration and biosimilar competition for Epi proColon, limited financial resources and negative profitability, and changes in healthcare policies and guidelines affecting cancer screening. The company's reliance on a single product (Epi proColon) also poses a risk, as any setbacks in its commercialization or market acceptance could significantly impact the company's financial performance.